NCT02995655已完成1 期
A Pilot Study of CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Overall response rate (partial response or higher)
研究概览
简要总结
The investigators hypothesize that CX-01 will disrupt the bone marrow microenvironment and increase the cytotoxic effects of azacitidine on myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) hematopoietic stem cells by disrupting the High-mobility group box protein 1 (HMGB1) interaction with toll-like receptor 4 (TLR4) and receptors for advanced glycation end products (RAGE), the CXC chemokine CXCL12/chemokine receptor 4 (CXCR4) axis, and by disrupting other leukocyte and vascular adhesion molecules. In addition, CX-01 may also help promote count recovery after treatment given its affinity for platelet factor-4 (PF4).
The selection of CX-01 dose for study in relapsed or refractory MDS and AML has been based upon the dual requirements to have sufficient drug administered to have potential activity but without clinically significant anticoagulation. The study dose chosen (4 mg/kg bolus followed by 0.25 mg/kg/hour) fulfills both of these criteria. In addition, this dose is expected to result in serum levels of CX-01 which are significantly higher than the IC90 identified in preclinical studies for inhibition of HMGB1-RAGE, toll-like receptor 2 (TLR2) and TLR4 interaction. Therefore, the chosen dose represents a rational balance between effective dosing and safety in thrombocytopenic patients with MDS and AML. This dose was previously established to be safe and tolerable when combined with cytarabine and idarubicin in patients with AML.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •One of the following diagnoses:
- •MDS with International Prostate Symptom Score (IPSS) score of INT-1 or higher and one of the following:
- •Symptomatic anemia with either hemoglobin < 10.0 g/dL or requiring red blood cell (RBC) transfusion
- •Thrombocytopenia with a history of two or more platelet counts < 50,000/µL or a significant hemorrhage requiring platelet transfusions
- •Neutropenia with two or more absolute neutrophil count (ANC) < 1,000/µL
- •Non-M3 AML
- •Prior treatment with ≥ 4 cycles of a hypomethylating agent (decitabine or azacitidine) without response OR documented disease progression on or after hypomethylating agent therapy
- •Age ≥ 18 years old
- •Adequate renal and hepatic function defined as all of the following:
- •total bilirubin ≤ 1.5 x upper limit of normal (ULN), except in cases of Gilbert's disease
- •aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN
- •serum creatinine < 2.0 x ULN
- •Peripheral blood blast count < 10,000/ µL.
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- •Females must be surgically or biologically sterile or postmenopausal or, if of childbearing potential, must agree to use an adequate method of contraception during the study until 30 days after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 30 days after the last treatment.
- •Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
排除标准
- •Prior allogeneic stem cell transplant
- •Central nervous system (CNS) leukemia
- •Diagnosed with AML and eligible for standard induction chemotherapy or stem cell transplantation.
- •At an increased risk of hemorrhage.
- •Known allergies, hypersensitivity, or intolerance to any form of heparin or azacitidine
- •Presence of significant active bleeding or condition requiring maintenance of a platelet count > 50,000/µL
- •Presence of any condition requiring any form of anticoagulant therapy (heparin flushes for IV catheter are permitted)
- •Receiving concomitant chemotherapy, radiation therapy, or immunotherapy during the duration of treatment on protocol, or within 21 days prior to enrollment
- •Known seropositivity for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
- •Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 28 days of study entry.
研究组 & 干预措施
CX-01 + Azacitidine
Experimental
- CX-01 will be administered as a 5-minute bolus infusion at a dose of 4mg/kg on Day 1 of each 28-day cycle, followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hour for Days 1 through 7 of each cycle. The dose of CX-01 should be calculated based on actual body weight (kg) as measured on Day 1 of each cycle.
- Azacitidine will be administered as a 15-minute intravenous infusion at a dose of 75mg/m^2 on Days 1-7 of each 28-day cycle. Azacitidine dose should be calculated based on actual body weight and height to determine BSA. CX-01 may be administered before or after azacitidine, at the discretion of the treating physician.
- Up to 6 cycles of treatment allowed
干预措施: CX-01 (Drug)
CX-01 + Azacitidine
Experimental
- CX-01 will be administered as a 5-minute bolus infusion at a dose of 4mg/kg on Day 1 of each 28-day cycle, followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hour for Days 1 through 7 of each cycle. The dose of CX-01 should be calculated based on actual body weight (kg) as measured on Day 1 of each cycle.
- Azacitidine will be administered as a 15-minute intravenous infusion at a dose of 75mg/m^2 on Days 1-7 of each 28-day cycle. Azacitidine dose should be calculated based on actual body weight and height to determine BSA. CX-01 may be administered before or after azacitidine, at the discretion of the treating physician.
- Up to 6 cycles of treatment allowed
干预措施: Azacitidine (Drug)
CX-01 + Azacitidine
Experimental
- CX-01 will be administered as a 5-minute bolus infusion at a dose of 4mg/kg on Day 1 of each 28-day cycle, followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hour for Days 1 through 7 of each cycle. The dose of CX-01 should be calculated based on actual body weight (kg) as measured on Day 1 of each cycle.
- Azacitidine will be administered as a 15-minute intravenous infusion at a dose of 75mg/m^2 on Days 1-7 of each 28-day cycle. Azacitidine dose should be calculated based on actual body weight and height to determine BSA. CX-01 may be administered before or after azacitidine, at the discretion of the treating physician.
- Up to 6 cycles of treatment allowed
干预措施: Bone marrow biopsy (Procedure)
CX-01 + Azacitidine
Experimental
- CX-01 will be administered as a 5-minute bolus infusion at a dose of 4mg/kg on Day 1 of each 28-day cycle, followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hour for Days 1 through 7 of each cycle. The dose of CX-01 should be calculated based on actual body weight (kg) as measured on Day 1 of each cycle.
- Azacitidine will be administered as a 15-minute intravenous infusion at a dose of 75mg/m^2 on Days 1-7 of each 28-day cycle. Azacitidine dose should be calculated based on actual body weight and height to determine BSA. CX-01 may be administered before or after azacitidine, at the discretion of the treating physician.
- Up to 6 cycles of treatment allowed
干预措施: Peripheral blood draw (Procedure)
结局指标
主要结局
Overall response rate (partial response or higher)
时间窗: 30 days following completion of treatment (estimated to be 28 weeks)
* Overall response rate = the percentage of patients obtaining partial response or higher * Patients will be assessed for response according to modified International Working Group (IWG) criteria
次要结局
- Progression-free survival (PFS)(Up to 5 years)
- Disease-free survival (DFS)(Up to 5 years)
- Overall survival (OS)(Up to 5 years)
- Safety and tolerability of regimen as measured by adverse events tabulated by patient(30 days following completion of therapy (estimated to be 28 weeks))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy VolunteersHealthyNCT01465139Celldex Therapeutics30
已完成
2 期
Azacitidine in Treating Patients With Chronic Myelomonocytic LeukemiaLeukemiaNCT01235117University of Leeds30
终止
1 期
Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAdult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic LeukemiaAdult Acute Monoblastic LeukemiaAdult Acute Monocytic LeukemiaAdult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With MaturationAdult Acute Myeloid Leukemia With Minimal DifferentiationAdult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLLAdult Acute Myeloid Leukemia Without MaturationAdult Acute Myelomonocytic LeukemiaAdult ErythroleukemiaAdult Pure Erythroid LeukemiaAlkylating Agent-Related Acute Myeloid LeukemiaRecurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaUntreated Adult Acute Myeloid LeukemiaNCT01260714National Cancer Institute (NCI)13
已完成
1 期
A Study to Assess the Levels of CAZ-AVI and Metronidazole in the Blood When Given Together and SeparatelyHealthyNCT01534247Pfizer28
已完成
1 期
Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaRecurrent Adult Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaNCT01249430National Cancer Institute (NCI)24